Breastfeeding women finally included in TB drug research

NCT ID NCT07069582

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how five common tuberculosis drugs move into breast milk after a single dose. Sixty healthy breastfeeding women in Indonesia will each receive one drug, and researchers will measure drug levels in their blood and milk. The goal is to gather safety data so that breastfeeding women can be included in future TB prevention trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rifampicin, isoniazid, levofloxacin, rifapentine, and bedaquiline
What this could lead to
If successful, this study could help include breastfeeding women in future TB prevention trials, ensuring safer dosing guidelines for mothers and infants.
What could go wrong
This is an early-phase, single-dose study in healthy volunteers, not patients. Results may not apply to women with TB or to repeated dosing, and drug levels in milk may vary widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREASTFEEDING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Universitas Padjadjaran, Klinik Penelitian Tuberculosis (TB Research Clinic)

    Bandung, West Java, 40161, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.